Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2011-10-25 Interim / Quarterly Rep…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 10 pages 60.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 September 2011.' It contains detailed operational updates, financial cash flow statements, and corporate matters for the quarter ending 30 September 2011. The presence of actual financial data such as consolidated cash flow statements and operational metrics indicates this is a substantive quarterly financial report. The document is approximately 15,000 characters long, which is consistent with a full report rather than a brief announcement. The content aligns with the definition of an Interim / Quarterly Report (IR), which includes comprehensive financial data and analysis for a period shorter than a full fiscal year. Therefore, the correct classification is IR. Q1 2012
2011-10-25 English
Forfeiture of options 1 page 36.1KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated October 24, 2011, regarding the forfeiture and cancellation of options previously issued to former employees. It provides specific details about the options forfeited, including ASX code, number of options, exercise price, and expiry date. The content is a straightforward announcement about a capital-related event (forfeiture of options) rather than a full report or detailed financial statement. The document length is short (1147 characters), and it does not contain financial statements or detailed analysis. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as option forfeitures.
2011-10-23 English
Presentation at AusBiotech 2011 National Conference 11 pages 991.5KB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated October 19, 2011, presenting a detailed investor presentation at the AusBiotech 2011 National Conference. It includes company highlights, forward-looking statements, product portfolio, financial snapshot for the year ending June 2011, and strategic information. The content is structured as a presentation with slides and detailed business and financial information aimed at investors. There is no indication that this is a full annual report or regulatory filing, nor is it a brief announcement or certification. The presence of detailed financial data, strategy, and market positioning aligns with the definition of an Investor Presentation (IP).
2011-10-18 English
Execution of Settlement and License Agreement with Hologic 2 pages 117.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated October 19, 2011, reporting the execution of a Settlement and License Agreement between Genetic Technologies Limited and Hologic, Inc. It references a patent infringement suit and settlement progress. The content is a corporate announcement about a legal settlement and licensing agreement, not a financial report, earnings release, or detailed management discussion. It does not contain financial statements or detailed financial data. The document is relatively short (4883 characters) and serves as a formal announcement to the market about a legal settlement and licensing agreement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and disclosures that do not fit other specific categories.
2011-10-18 English
BREVAGen changing the way US physicians assess breast cancer 3 pages 49.7KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated October 18, 2011, from Genetic Technologies Limited. It discusses the early US roll-out and physician endorsement of their BREVAGen™ breast cancer risk assessment test. The content focuses on product launch progress, marketing strategy, clinical validation, and company background. There are no financial statements, regulatory filings, voting results, or management changes. The document is a corporate announcement about a product and business update rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) because it relates to commercial rollout and market expansion of a product, which is often included in capital or financing updates. Confidence is high given the clear nature of the announcement as a business update on product commercialization.
2011-10-17 English
Annual Report to shareholders 101 pages 2.6MB
Annual Report Classification · 100% confidence The document is titled '2011 Annual Report' and is an extensive report of approximately 15,000 characters. It includes detailed sections such as Chairman's Message, CEO's Message, financial highlights, corporate governance statement, consolidated financial statements, notes to financial statements, directors' report, auditor's report, and other comprehensive information typical of a full annual report. The document also references the fiscal year 2010-11 and discusses company strategy, financial performance, and operational highlights in detail. There is no indication that this is merely an announcement or a summary; rather, it contains substantive financial and operational data. Therefore, this document fits the definition of an Annual Report (10-K). FY 2011
2011-10-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.